Zhongyu Zhu

Summary

Affiliation: National Cancer Institute
Country: USA

Publications

  1. pmc Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies
    Zhongyu Zhu
    CCRNP, CCR, NCI Frederick, NIH, Frederick, MD 21702, USA
    J Virol 80:891-9. 2006
  2. ncbi request reprint Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra
    Li Rong Yu
    Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC Frederick, Inc, NCI Frederick, P O Box B, Frederick, Maryland 21702, USA
    J Proteome Res 6:4150-62. 2007
  3. doi request reprint Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody
    Zhongyu Zhu
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, Center for Cancer Research, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702 1201, USA
    J Infect Dis 197:846-53. 2008
  4. ncbi request reprint Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses
    Zhongyu Zhu
    Protein Interactions Group, CCRNP, BRP, SAIC Frederick, Inc, NCI Frederick, NIH Bldg 469, Rm 139, PO Box B, MD 21702 1201, USA
    Expert Rev Anti Infect Ther 4:57-66. 2006
  5. doi request reprint Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics
    Weizao Chen
    Protein Interactions Group, Frederick National Laboratory for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland 21702, USA
    Mol Cancer Ther 11:1400-10. 2012
  6. pmc Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity
    Qi Zhao
    Protein Interactions Group, National Cancer Institute Frederick, NIH, Bldg 469, Rm 150B, Frederick, MD 21702, USA
    Mol Cancer Ther 10:1677-85. 2011
  7. pmc Construction of a human antibody domain (VH) library
    Weizao Chen
    NCI Frederick, National Institutes of Health, Frederick, MD, USA
    Methods Mol Biol 525:81-99, xiii. 2009
  8. pmc Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains
    Weizao Chen
    Protein Interactions Group, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA
    J Virol 88:1125-39. 2014
  9. pmc Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates
    Weizao Chen
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute NCI Frederick, National Institutes of Health NIH, Frederick, MD 21702 1201, USA
    Antiviral Res 88:107-15. 2010
  10. pmc Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses
    Ponraj Prabakaran
    Protein Interactions, CCRNP, NCI Frederick, NIH, Building 469, 150B, P O Box B, Miller Drive, Frederick, MD 21702 1201, USA
    Expert Opin Biol Ther 9:355-68. 2009

Detail Information

Publications37

  1. pmc Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies
    Zhongyu Zhu
    CCRNP, CCR, NCI Frederick, NIH, Frederick, MD 21702, USA
    J Virol 80:891-9. 2006
    ....
  2. ncbi request reprint Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra
    Li Rong Yu
    Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC Frederick, Inc, NCI Frederick, P O Box B, Frederick, Maryland 21702, USA
    J Proteome Res 6:4150-62. 2007
    ..The study also indicates that evaluation of confidence levels for phosphopeptide identification via the reversed sequence database searching strategy might underestimate the false positive rate...
  3. doi request reprint Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody
    Zhongyu Zhu
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, Center for Cancer Research, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702 1201, USA
    J Infect Dis 197:846-53. 2008
    ..These results suggest that m102.4 has potential as a therapeutic agent for the treatment of diseases caused by henipaviruses. It could be also used for prophylaxis and diagnosis, and as a research reagent...
  4. ncbi request reprint Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses
    Zhongyu Zhu
    Protein Interactions Group, CCRNP, BRP, SAIC Frederick, Inc, NCI Frederick, NIH Bldg 469, Rm 139, PO Box B, MD 21702 1201, USA
    Expert Rev Anti Infect Ther 4:57-66. 2006
    ....
  5. doi request reprint Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics
    Weizao Chen
    Protein Interactions Group, Frederick National Laboratory for Cancer Research, National Cancer Institute, NIH, Frederick, Maryland 21702, USA
    Mol Cancer Ther 11:1400-10. 2012
    ..This approach could also be used to irreversibly eliminate other disease-related soluble ligands...
  6. pmc Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity
    Qi Zhao
    Protein Interactions Group, National Cancer Institute Frederick, NIH, Bldg 469, Rm 150B, Frederick, MD 21702, USA
    Mol Cancer Ther 10:1677-85. 2011
    ..2. These results suggest that m708.5 could have potential as a candidate therapeutic for cancers driven by the IGF-I and IGF-II interactions with IGF1R and IR...
  7. pmc Construction of a human antibody domain (VH) library
    Weizao Chen
    NCI Frederick, National Institutes of Health, Frederick, MD, USA
    Methods Mol Biol 525:81-99, xiii. 2009
    ..Here, we describe the construction of a phage-displayed VH library and an approach to introduce genetic diversity in this library, where both diverse human CDRs and synthetic CDRs are combined into a single-domain (VH) framework...
  8. pmc Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains
    Weizao Chen
    Protein Interactions Group, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland, USA
    J Virol 88:1125-39. 2014
    ..Therefore, mD1.22 and related fusion proteins could be useful for HIV-1 prevention and therapy, including eradication of the virus. ..
  9. pmc Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates
    Weizao Chen
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute NCI Frederick, National Institutes of Health NIH, Frederick, MD 21702 1201, USA
    Antiviral Res 88:107-15. 2010
    ....
  10. pmc Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses
    Ponraj Prabakaran
    Protein Interactions, CCRNP, NCI Frederick, NIH, Building 469, 150B, P O Box B, Miller Drive, Frederick, MD 21702 1201, USA
    Expert Opin Biol Ther 9:355-68. 2009
    ....
  11. pmc A large human domain antibody library combining heavy and light chain CDR3 diversity
    Weizao Chen
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702 1201, USA
    Mol Immunol 47:912-21. 2010
    ..The new library could be used not only for the selection of such dAbs thus complementing existing libraries but also as a research tool for the exploration of the mechanisms determining folding and stability of human antibody domains...
  12. doi request reprint Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1
    Zhongyu Zhu
    Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
    Virol Sin 28:71-80. 2013
    ..Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics...
  13. pmc Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens
    Xiaodong Xiao
    Protein Interactions Group, CCRNP, NCI Frederick, NIH, Frederick, MD 21702, USA
    Biochem Biophys Res Commun 390:404-9. 2009
    ..This hypothesis, if further supported by data, could contribute to our understanding of how HIV-1 evades immune responses and offer new concepts for design of effective vaccine immunogens...
  14. pmc Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies
    Weizao Chen
    Protein Interactions Group, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
    Biochem Biophys Res Commun 425:931-7. 2012
    ....
  15. doi request reprint Yeast display of engineered antibody domains
    Qi Zhao
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
    Methods Mol Biol 899:73-84. 2012
    ..The highest affinity clones from the final round of maturation were identified and analyzed. We discuss extensively each key step, and provide detailed protocols and helpful notes...
  16. pmc A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity
    Yang Feng
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute Frederick, NIH, Frederick, Maryland 21702 1201, USA
    Mol Cancer Ther 8:1113-8. 2009
    ..M912 is the first reported fully human monoclonal antibody to mesothelin, which has potential for cancer treatment and diagnosis...
  17. pmc Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6
    Gilad Ofek
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 88:2426-41. 2014
    ..Antibodies m66, m66.6, and 2F5 thus utilize similar mechanistic elements to recognize a common gp41-MPER epitope and to neutralize HIV-1. ..
  18. pmc Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies
    Zhongyu Zhu
    National Cancer Institute, Frederick, Maryland 21702 1201, USA
    J Virol 85:11401-8. 2011
    ....
  19. pmc Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens
    Weizao Chen
    Miller Drive, Building 469, Room 150B, Frederick, MD 21702 1201, USA
    J Virol 85:9395-405. 2011
    ..Our approach could be applied to other cases where soluble isolated protein domains are needed...
  20. ncbi request reprint Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function
    Yang Feng
    Protein Interactions Group, Nanobiology Program, Center for Cancer Research, National Cancer Institute Frederick, NIH Building 469, Frederick, MD 21702 1201, USA
    Mol Cancer Ther 5:114-20. 2006
    ....
  21. pmc Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
    Zhongyu Zhu
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, SAIC Frederick, Inc, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 104:12123-8. 2007
    ..These antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections...
  22. pmc Characterization of human IgG repertoires in an acute HIV-1 infection
    Weizao Chen
    Protein Interactions Group, National Cancer Institute, National Institutes of Health NIH, Frederick, Maryland 21702, USA
    Exp Mol Pathol 93:399-407. 2012
    ....
  23. pmc A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity
    Yang Feng
    Protein Interactions Group, CCRNP, NCI Frederick, NIH, 1050 Boyle Street, Frederick, MD 21702, USA
    Arthritis Res Ther 13:R59. 2011
    ..In this study we aimed to develop an FRβ-specific human monoclonal antibody (mAb) that could be used as a therapeutic agent to treat rheumatoid arthritis and other autoimmune diseases, as well as FRβ positive cancers...
  24. pmc Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers
    Weizao Chen
    Protein Interactions Group, CCRNP, CCR, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702, USA
    Proc Natl Acad Sci U S A 105:17121-6. 2008
    ....
  25. ncbi request reprint Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains
    Weizao Chen
    Miller Drive, Building 469, Room 150B, Frederick, MD 21702 1201, USA
    Curr Drug Discov Technol 11:28-40. 2014
    ....
  26. pmc Highly efficient selection of epitope specific antibody through competitive yeast display library sorting
    Vinita Puri
    Protein Interactions Group, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD USA
    MAbs 5:533-9. 2013
    ....
  27. pmc Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing
    Ponraj Prabakaran
    CCR Nanobiology Program, Protein Interactions Group, Frederick National Laboratory for Cancer Research, National Institutes of Health NIH, Frederick MD, USA
    Front Microbiol 3:277. 2012
    ....
  28. ncbi request reprint Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody
    Ponraj Prabakaran
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, NCI, National Institutes of Health, Frederick, Maryland 21702, USA
    J Biol Chem 281:15829-36. 2006
    ..The available structural information indicates that the SCV entry may not be mediated by ACE2-induced conformational changes in the RBD but may involve other conformational changes or/and yet to be identified coreceptors...
  29. pmc Identification and characterization of fully human anti-CD22 monoclonal antibodies
    Xiaodong Xiao
    Protein Interactions Group, CCRNP, NCI Frederick, NIH, Frederick, MD 21702 1201, USA
    MAbs 1:297-303. 2009
    ..Their epitopes do not overlap with those of several therapeutic antibodies currently in preclinical or clinical development. These antibodies have potential as cancer therapeutic candidates and research reagents...
  30. pmc Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody
    Yang Feng
    Protein Interactions Group, CCRNP, NCI Frederick, NIH, Frederick, MD, USA
    MAbs 2:565-70. 2010
    ..This antibody may have potential for further development as a candidate therapeutic and research tool...
  31. pmc Multiple site-specific in vitro labeling of single-chain antibody
    Boopathy Ramakrishnan
    Center for Cancer Research Nanobiology Program, Center for Cancer Research, NCI Frederick, Frederick, Maryland 21702, USA
    Bioconjug Chem 20:1383-9. 2009
    ....
  32. pmc Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain
    Weizao Chen
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702 1201, USA
    J Mol Biol 382:779-89. 2008
    ..This library could be a valuable source of antibodies targeting size-restricted epitopes and antigens in obstructed locations where efficient penetration could be critical for successful treatment...
  33. pmc Identification of a putative Crimean-Congo hemorrhagic fever virus entry factor
    Xiaodong Xiao
    Protein Interactions Group, CCR Nanobiology Program, NCI Frederick, NIH, Frederick, MD 21702, USA
    Biochem Biophys Res Commun 411:253-8. 2011
    ..The identification of the CCHFV RBD and its binding partner could provide novel targets for therapy and tools for prevention as well as more complete understanding of the mechanisms of CCHFV entry and pathogenesis...
  34. pmc Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model
    Xiaodong Xiao
    Protein Interactions Group, Center for Cancer Research Nanobiology Program, National Cancer Institute Frederick, National Institutes of Health, Frederick, Maryland, United States of America
    PLoS ONE 5:e13047. 2010
    ..Incomplete to complete protection was achieved when m252 was given at different times post-challenge. These antibodies can be further studied to determine their potential as therapeutics or prophylactics in Y. pestis infection in humans...
  35. pmc Construction of a large naïve human phage-displayed Fab library through one-step cloning
    Zhongyu Zhu
    NCI Frederick, National Institutes of Health, Frederick, MD, USA
    Methods Mol Biol 525:129-42, xv. 2009
    ..Optimization of each key step is extensively discussed and simplified protocols for library panning and Fab production are also described...
  36. pmc Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding
    Kimberly A Bishop
    Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
    J Virol 82:11398-409. 2008
    ..Together, these data suggest the stalk domain of G plays an important role in the conformational stability and receptor binding-triggered changes leading to productive fusion, such as the dissociation of G and F...
  37. ncbi request reprint Functional studies of host-specific ephrin-B ligands as Henipavirus receptors
    Katharine N Bossart
    CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria 3220, Australia
    Virology 372:357-71. 2008
    ....